Funding Opportunities for Fragile X Research 2017-18

2017-18 Priorities for FRAXA Research Grants

FRAXA has funded more than $26 million in medical research aimed at finding specific treatments and ultimately a cure for fragile X syndrome. FRAXA awards two categories of grants, and guidelines for these grants have changed significantly from previous years. The purpose of the changes is to place a greater emphasis on clinical trials, while still continuing to fund worthwhile translational research and other early-stage work.

Focus is on Clinical Trials

The previous category of "FRAXA Program Grants" has been eliminated, in part because these grants have not focused on clinical research to the desired extent. In its place, we are introducing FRAXA Clinical Trial Grants. These grants are strictly for clinical research with fragile X subjects. Strong emphasis will be placed on clinical trials of potentially disease-modifying agents which have been previously validated in fragile X animal models. Other types of clinical research may be considered, such as biomarker studies in fragile X patients, or trials of symptomatic therapies; however, these will be accorded lower priority in funding decisions. Budgets and grant structure are flexible but may be subject to some negotiation.

Letters of Intent are required for submission of Clinical Trial Grant applications. We are flexible about deadlines for submission, given the complexities of organizing clinical research.

Summary - Clinical Trial Grants

• Flexible in amount and duration.
• Must involve human subjects with fragile X.
• Highest priority is given to clinical trials of potentially disease-modifying therapeutics which have previously been validated in fragile X animal models.
• Applications may be submitted at any time, but a Letter of Intent (LOI) to Michael Tranfaglia, MD is essential.

HOW TO APPLY